PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for CONAMEU Urología

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More CONACEM Medical Specialty Board Certification Examinations (Mexico)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Consejo Mexicano de Certificación en Pediatría — Certificación en Pediatría (Mexico)

Practice Questions

Consejo Mexicano de Medicina de Urgencias — Certificación en Medicina de Urgencias (Mexico)

Practice Questions

Consejo Mexicano de Psiquiatría — Certificación en Psiquiatría (Mexico)

Practice Questions

Consejo Mexicano de Radiología e Imagen — Certificación en Radiología e Imagen (Mexico)

Practice Questions

Consejo Mexicano de Cirugía General — Certificación en Cirugía General (Mexico)

Practice Questions

Consejo Mexicano de Dermatología — Certificación en Dermatología (Mexico)

Practice Questions
Exam Review

Key Facts: CONAMEU Urología Exam

≥ 300 MCQs

Written-stage items, up to 3 hours

CONAMEU Reglamento 2023

60 min

Maximum oral stage (clinical cases before 5–6 sinodales)

CONAMEU Reglamento 2023

MXN 6,000

Certification exam fee

CONAMEU — Certificación

5 Sep 2026

Virtual oral phase of the 2026-2 cycle

CONAMEU — Aprobados 2026-2

250 points

Recertification by points over 5 years (or a 300-item exam)

CONAMEU FAQ

The CONAMEU exam is the CONACEM-recognized board certification exam for urology in Mexico: a written test of at least 300 MCQs in up to 3 hours, then an oral clinical-case exam before a jury. The fee is MXN 6,000, and certification is renewed every 5 years.

Sample CONAMEU Urología Practice Questions

Try these sample questions to review concepts for the CONAMEU Urología exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 56-year-old asymptomatic man undergoes routine health screening. His total prostate-specific antigen (PSA) is 5.2 ng/mL, and digital rectal examination (DRE) reveals a smooth, non-tender prostate without nodules (cT1c). A repeat total PSA after 4 weeks is 5.4 ng/mL with a free-to-total PSA ratio of 9%. According to clinical practice guidelines, what is the most appropriate next step in management?
A.Multiparametric magnetic resonance imaging (mpMRI) of the prostate followed by targeted biopsy
B.Empirical treatment with ciprofloxacin for 4 weeks followed by repeat total PSA measurement
C.Immediate transrectal ultrasound-guided systematic 6-core sextant needle biopsy alone
D.Reassurance and annual surveillance of total PSA given the absence of palpable abnormalities
Explanation: In a patient with a confirmed total PSA in the diagnostic gray zone (4.0–10.0 ng/mL) and a low free-to-total PSA ratio (<10%, which confers a >50% probability of prostate cancer), further diagnostic evaluation is indicated. Current EAU guidelines recommend multiparametric magnetic resonance imaging (mpMRI) before prostate biopsy. If suspicious lesions are identified (PI-RADS 3–5), targeted biopsy combined with systematic biopsy provides superior detection of clinically significant prostate cancer while minimizing overdiagnosis of indolent disease.
2A 64-year-old man undergoes prostate biopsy after an elevated PSA of 6.8 ng/mL. Histopathological evaluation reveals adenocarcinoma with a primary Gleason pattern of 3 and a secondary Gleason pattern of 4 (Gleason score 3+4=7) involving 3 of 12 cores. According to the International Society of Urological Pathology (ISUP) consensus, which Grade Group corresponds to this tumor?
A.ISUP Grade Group 1
B.ISUP Grade Group 2
C.ISUP Grade Group 3
D.ISUP Grade Group 4
Explanation: Under the ISUP Grade Group system, Gleason score 3+4=7 corresponds to ISUP Grade Group 2. This distinct category carries a significantly better prognosis than Gleason score 4+3=7 (ISUP Grade Group 3), because the predominant pattern is well-formed glands (pattern 3) rather than poorly formed, fused, or cribriform glands (pattern 4). Grade Group 1 corresponds to Gleason ≤6, Grade Group 4 corresponds to Gleason 8 (4+4, 3+5, 5+3), and Grade Group 5 corresponds to Gleason 9–10.
3A 62-year-old man with a persistent serum PSA of 7.1 ng/mL undergoes multiparametric magnetic resonance imaging (mpMRI) of the prostate. The radiologist identifies a 14 mm focal lesion in the peripheral zone of the right midgland that demonstrates markedly hypointense signal on the apparent diffusion coefficient (ADC) map and markedly hyperintense signal on high b-value diffusion-weighted imaging (DWI), without definitive extraprostatic extension. According to the PI-RADS v2.1 guidelines, what is the assigned PI-RADS score?
A.PI-RADS 2
B.PI-RADS 3
C.PI-RADS 4
D.PI-RADS 5
Explanation: In the peripheral zone (PZ), diffusion-weighted imaging (DWI/ADC) is the dominant sequence under PI-RADS v2.1. A focal lesion demonstrating marked hypointensity on ADC and marked hyperintensity on high b-value DWI that measures <15 mm in greatest dimension and lacks extraprostatic extension is classified as PI-RADS 4 (clinically significant cancer is likely). To meet the criteria for PI-RADS 5, the lesion must measure ≥15 mm in greatest dimension or exhibit definite extraprostatic extension or invasive behavior.
4A 68-year-old man is diagnosed with localized adenocarcinoma of the prostate. His diagnostic evaluation shows: clinical stage T2b on digital rectal examination, serum total PSA 14.5 ng/mL, and biopsy revealing ISUP Grade Group 2 (Gleason 3+4=7) in 4 of 12 cores. Bone scintigraphy and contrast-enhanced CT of the abdomen and pelvis demonstrate no evidence of distant or nodal metastases. According to NCCN risk stratification, into which category is this patient classified?
A.Low-risk localized prostate cancer
B.Favorable intermediate-risk localized prostate cancer
C.Unfavorable intermediate-risk localized prostate cancer
D.High-risk localized prostate cancer
Explanation: Intermediate-risk prostate cancer is defined by cT2b–cT2c, PSA 10–20 ng/mL, or ISUP Grade Group 2–3. To distinguish favorable from unfavorable intermediate risk: favorable intermediate risk requires having only one intermediate risk factor, ISUP Grade Group 1 or 2, and <50% positive biopsy cores. Unfavorable intermediate risk is defined by having ISUP Grade Group 3, OR ≥50% positive biopsy cores, OR two or more intermediate risk factors (cT2b/c, PSA 10–20, Grade Group 2/3). This patient has three intermediate risk factors (cT2b, PSA 14.5 ng/mL, and Grade Group 2), which places him in the unfavorable intermediate-risk category.
5A 58-year-old man with a serum PSA of 4.8 ng/mL and normal digital rectal examination undergoes prostate biopsy that confirms ISUP Grade Group 1 (Gleason 3+3=6) adenocarcinoma in 2 of 14 cores, with maximum core involvement of 20%. He is asymptomatic, healthy, and interested in active surveillance. Which of the following represents a standard active surveillance monitoring schedule during the first 1 to 2 years?
A.Serial PSA every 3–6 months, DRE every 6–12 months, and confirmatory/surveillance MRI with biopsy at 12–24 months
B.Continuous administration of finasteride 5 mg daily with annual computed tomography of the abdomen and pelvis
C.Annual bone scintigraphy combined with biannual transurethral resection of the prostate (TURP)
D.Prophylactic pelvic radiation therapy delivered at 12 months if serum PSA does not spontaneously decrease
Explanation: Active surveillance is the preferred management strategy for men with low-risk localized prostate cancer (cT1c–T2a, PSA <10 ng/mL, ISUP Grade Group 1, low core volume). Protocols vary (e.g., PRIAS, EAU, NCCN), but they typically include serum PSA every 3 to 6 months, digital rectal examination every 6 to 12 months, and repeat mpMRI with confirmatory or surveillance biopsy within 12 to 24 months. These detect sampling error or upgrading before expectant management continues.
6A 60-year-old potent man with localized prostate cancer (cT1c, PSA 5.8 ng/mL, ISUP Grade Group 2 involving 10% of one right peripheral lobe core) is scheduled for robot-assisted radical prostatectomy. He strongly desires preservation of erectile function. In which scenario is bilateral nerve-sparing surgery most safely contraindicated?
A.A clinical stage cT1c lesion with contralateral low-volume ISUP Grade Group 1 disease
B.High suspicion or MRI evidence of macroscopic extracapsular extension abutting the neurovascular bundle
C.A total prostate volume of 65 cc on preoperative transrectal ultrasonography
D.Prior history of uncomplicated bilateral laparoscopic inguinal hernia repair with mesh
Explanation: Nerve-sparing radical prostatectomy aims to preserve the autonomic cavernous nerves traveling within the neurovascular bundles along the posterolateral prostatic capsule. The principal oncological contraindication to ipsilateral or bilateral nerve sparing is the presence of palpable or MRI-detected extracapsular extension (cT3a) in direct proximity to or invading the neurovascular bundle. Preserving the bundle in such cases carries an unacceptably high risk of positive surgical margins, compromising oncologic control.
7A 71-year-old man is diagnosed with high-risk localized adenocarcinoma of the prostate (cT3a by MRI, PSA 24 ng/mL, ISUP Grade Group 4). Metastatic staging with CT and bone scan is negative. He is scheduled to undergo definitive external beam radiation therapy (EBRT). According to randomized clinical trials and international guidelines, what is the recommended duration of concurrent and adjuvant androgen deprivation therapy (ADT)?
A.Short-term ADT for 4 to 6 months
B.Neoadjuvant ADT for 1 month only without adjuvant therapy
C.Long-term ADT for 24 to 36 months
D.Lifelong continuous ADT until disease progression
Explanation: Multiple landmark phase III randomized trials (including EORTC 22961 and RTOG 9202) have established that for men with high-risk or locally advanced localized prostate cancer receiving definitive EBRT, long-term androgen deprivation therapy (ADT) lasting 24 to 36 months confers significant overall survival and metastasis-free survival benefits compared with short-term (4–6 months) ADT. The PCS IV trial suggests 18 months may be sufficient for some patients. Short-term ADT (4–6 months) is the standard regimen for intermediate-risk, not high-risk, disease.
8Which of the following thresholds defines biochemical recurrence (BCR) of prostate cancer following radical prostatectomy versus definitive external beam radiotherapy (EBRT)?
A.Two consecutive PSA values ≥0.5 ng/mL after radical prostatectomy; nadir + 1.0 ng/mL after EBRT
B.A single PSA value >1.0 ng/mL after radical prostatectomy; any rise >0.2 ng/mL after EBRT
C.PSA >0.4 ng/mL confirmed by second reading after radical prostatectomy; nadir + 0.5 ng/mL after EBRT
D.Two consecutive PSA values ≥0.2 ng/mL after radical prostatectomy; nadir + 2.0 ng/mL after EBRT (Phoenix criteria)
Explanation: By international consensus (AUA/ASTRO and EAU guidelines), biochemical recurrence following radical prostatectomy is defined as a confirmed serum PSA of ≥0.2 ng/mL, followed by a second confirmatory value ≥0.2 ng/mL. In contrast, following definitive external beam radiotherapy (with or without ADT), the prostate remains in situ and normally produces low baseline PSA levels; therefore, biochemical recurrence is defined by the Phoenix consensus criteria as an increase in serum PSA of ≥2.0 ng/mL above the post-treatment nadir value.
9A 66-year-old man who underwent radical prostatectomy 3 years ago develops biochemical recurrence with a confirmed PSA of 0.65 ng/mL and a PSA doubling time of 7 months. Conventional CT of the abdomen/pelvis and technetium-99m bone scintigraphy show no abnormalities. Which molecular imaging modality offers the highest diagnostic sensitivity for localizing recurrence at this PSA level?
A.Prostate-specific membrane antigen (PSMA) PET/CT with 68Ga-PSMA-11 or 18F-DCFPyL
B.Fluorodeoxyglucose (18F-FDG) PET/CT whole-body imaging
C.Technetium-99m labeled red blood cell scintigraphy
D.Indium-111 capromab pendetide (ProstaScint) planar imaging
Explanation: Prostate-specific membrane antigen (PSMA) PET/CT (using tracers such as 68Ga-PSMA-11 or 18F-DCFPyL) has revolutionized the detection of recurrent prostate cancer. At low PSA levels between 0.5 and 1.0 ng/mL, PSMA PET/CT demonstrates a detection rate exceeding 50–70%, significantly outperforming conventional imaging, choline PET, and FDG PET. Identifying whether recurrence is localized to the prostatic bed, pelvic lymph nodes, or distant sites directly guides salvage radiotherapy or targeted metastasis-directed therapy.
10A 67-year-old man presents with bone pain and is diagnosed with de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC), with multiple vertebral metastases and retroperitoneal lymphadenopathy (CHAARTED criteria: high volume). He has an ECOG performance status of 1 and no severe cardiovascular comorbidities. Based on landmark phase III clinical trials (PEACE-1, ARASENS), what is the most effective first-line systemic regimen?
A.Androgen deprivation therapy (ADT) monotherapy with surgical or medical castration alone
B.Triplet therapy combining ADT, docetaxel chemotherapy (6 cycles), and an androgen receptor pathway inhibitor (abiraterone or darolutamide)
C.ADT combined with first-generation antiandrogen bicalutamide 50 mg daily
D.Docetaxel chemotherapy alone without androgen deprivation therapy
Explanation: Landmark phase III randomized trials (PEACE-1 and ARASENS) established that for patients with fit, de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC), triplet therapy consisting of ADT + docetaxel (6 cycles) + an androgen receptor pathway inhibitor (ARPI: abiraterone acetate plus prednisone, or darolutamide) significantly prolongs overall survival and delays radiographic progression compared with ADT plus docetaxel. ADT plus an ARPI alone (doublet) remains an accepted standard; triplet therapy has not been directly compared with it. ADT monotherapy is suboptimal care for fit patients with high-volume mHSPC.

About the CONAMEU Urología Exam

Independent study practice by OpenExamPrep for the certification exam of the Consejo Nacional Mexicano de Urología, A.C. (CONAMEU), a CONACEM-recognized specialty council. The official exam has a written stage of at least 300 multiple-choice items (up to 3 hours) followed by an oral clinical-case exam before a jury (up to 60 minutes); the fee is MXN 6,000. This bank is an independent English-language MCQ study adaptation of the written-stage content built on current international urology guidelines; it is not an official translation or simulation of the Spanish-language CONAMEU exam and does not reproduce the oral stage.

Exam sponsor: Consejo Nacional Mexicano de Urología, A.C.. The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

CONAMEU certification has two stages and is held at least once a year. The written stage has at least 300 multiple-choice items, with up to 3 hours to answer. Candidates who pass it take the oral stage: structured objective clinical cases (CCEO) before a jury of five or six sinodales, lasting up to 60 minutes. Results are communicated within 20 business days. In the 2026-2 cycle, the oral phase took place virtually on 5 September 2026.

Time Limit

Up to 3 hours (written) + up to 60 minutes (oral)

Passing Score

not-published

Exam / Certification Fees

MXN 6,000

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

Weight not published

Uro-oncología

Prostate cancer (MRI-first diagnosis, ISUP grade groups, NCCN risk groups, active surveillance, radiotherapy with ADT, PSMA PET, mHSPC and CRPC systemic therapy), NMIBC and MIBC, renal cell carcinoma, testicular germ cell tumors, and penile cancer

Weight not published

Litiasis Urinaria y Endourología

Stone composition and metabolic evaluation, medical expulsive therapy, obstructed infected kidney, SWL, ureteroscopy and laser settings, PCNL and its complications, and medical prevention

Weight not published

Urología Funcional, HPB e Incontinencia

BPH pathophysiology, medical therapy (MTOPS, CombAT), surgical and minimally invasive options, stress and urgency incontinence, OAB therapies (AUA/SUFU 2024), urodynamics, and neurogenic bladder

Weight not published

Reconstructiva, Trauma e Infecciones

Urethral stricture and urethroplasty, renal, bladder, urethral, penile, and testicular trauma (AAST), IDSA 2025 complicated UTI, prostatitis, Fournier gangrene, and emphysematous pyelonephritis

Weight not published

Andrología y Urología Pediátrica

WHO 6th edition semen analysis, varicocele, azoospermia and Y microdeletions, erectile dysfunction and priapism, Peyronie disease, cryptorchidism, hypospadias, and vesicoureteral reflux

Preparing for the CONAMEU Urología Exam

What You Need to Know

  • Passing score: not-published
  • Assessment: CONAMEU certification has two stages and is held at least once a year. The written stage has at least 300 multiple-choice items, with up to 3 hours to answer. Candidates who pass it take the oral stage: structured objective clinical cases (CCEO) before a jury of five or six sinodales, lasting up to 60 minutes. Results are communicated within 20 business days. In the 2026-2 cycle, the oral phase took place virtually on 5 September 2026.
  • Time limit: Up to 3 hours (written) + up to 60 minutes (oral)
  • Exam / certification fees: MXN 6,000 Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

CONAMEU Urología: Suggested Study Strategy

1Pace yourself for the written stage: 300 or more items in up to 3 hours leaves about 36 seconds per item.
2Prepare for the oral stage separately by presenting structured clinical cases aloud: diagnosis, staging, management options, and complications.
3Keep current with recent changes: IDSA 2025 complicated-UTI definitions, AUA/SUFU 2024 OAB guidance, Bosniak v2019, WHO 2022 renal tumor classification, and the NOSTONE thiazide trial.
4Master risk stratification tables: NCCN prostate risk groups, EAU NMIBC risk groups, IMDC for kidney cancer, and IGCCCG for germ cell tumors.
5Review emergency algorithms: obstructed infected kidney, Fournier gangrene, ischemic priapism, pelvic fracture urethral injury, and autonomic dysreflexia.

Frequently Asked Questions

How is the CONAMEU certification exam structured?

The CONAMEU Reglamento describes two stages. The written exam has at least 300 multiple-choice items and a maximum of 3 hours. The oral exam uses structured objective clinical cases before a jury of five or six sinodales and lasts up to 60 minutes. Only candidates who pass the written stage go on to the oral stage.

How do I apply and what does it cost?

Candidates complete two routes: an electronic file in SIGME (identity documents, medical title and cédula, specialty diploma or teaching-department letter) and a mailed packet with an application letter endorsed by two recertified urologists, two studio photographs, a tax status certificate, and the original receipt for the MXN 6,000 fee. Residency must have lasted at least five years.

When is the exam held?

The exam is held at least once a year at venues set by the council. In the 2026-2 cycle, the written-exam pass list was published and the oral phase was held virtually on 5 September 2026. Check conameu.org for the next cycle.

How is certification renewed?

Certification is renewed every 5 years, either by accumulating 250 points in clinical and continuing-education activities or by passing a 300-item written recertification exam.

Why is this practice bank in English, and does it cover the oral exam?

The CONAMEU exam is conducted in Spanish. This OpenExamPrep bank is an independent English-language MCQ study adaptation of the written-stage content; it is not an official translation or simulation of the CONAMEU exam, and it does not reproduce the oral clinical-case stage.